Medigene Valuation

Is MDG1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDG1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDG1?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MDG1. This is calculated by dividing MDG1's market cap by their current preferred multiple.
What is MDG1's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	€31.61m

MDG1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	-1.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MDG1's PS Ratio compare to its peers?

The above table shows the PS ratio for MDG1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.8x
RLF Relief Therapeutics Holding	3.8x	n/a	CHF 32.4m
ADXN Addex Therapeutics	4.9x	0.7%	CHF 6.8m
MOLN Molecular Partners	18.6x	53.0%	CHF 146.1m
BSLN Basilea Pharmaceutica	3.8x	9.2%	CHF 563.6m
MDG1 Medigene	4.2x	16.1%	CHF 31.6m

Price-To-Sales vs Peers: MDG1 is good value based on its Price-To-Sales Ratio (4.2x) compared to the peer average (7.8x).

Price to Earnings Ratio vs Industry

How does MDG1's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: MDG1 is good value based on its Price-To-Sales Ratio (4.2x) compared to the European Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is MDG1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDG1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.2x
Fair PS Ratio	2x

Price-To-Sales vs Fair Ratio: MDG1 is expensive based on its Price-To-Sales Ratio (4.2x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.